Medindia

X

PharmaNet Development Group Symposia 'Crossing the Bridge from Preclinical to Clinical Studies' to be Held February 2010 in Basel, Dusseldorf and Vienna

Tuesday, January 12, 2010 General News J E 4
Advertisement
PRINCETON, N.J., Jan. 11 PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, is pleased to announce that it is hosting a complementary symposium and round table discussion entitled "Crossing the Bridge from Preclinical to Clinical Studies".

Recently, the Company successfully hosted a similar symposium in Sweden. Due to its success, the Company will be hosting the event in other important biotechnology centers in Europe. The symposia will be held in:

Basel, Switzerland on 9 February 2010

Dusseldorf, Germany on 10 February 2010

Vienna, Austria on 11 February 2010

Robert Reekie, Senior Executive Vice President, Europe and Asia-Pacific, said, "This symposium demonstrates PharmaNet's commitment to the European Biotech sector and the expertise that we can bring to clinical programs as we assist biopharmaceutical companies commercialise their products efficiently."

Whether facing complex regulatory requirements, conducting first-in-man studies, or developing clinical development plans for late stage clinical trials, PharmaNet senior-level professionals assist biopharmaceutical companies in navigating this critical stage of drug development. With established credentials, proven experience, and insight acquired through working with international regulatory agencies, PharmaNet provides viable strategies to conduct studies from Phase I through Phase IV utilizing its global network of resources.

For Phase I clinical development, the Company's clinics have more than 300 beds and access to numerous special populations. For Phase II-IV clinical development programs, PharmaNet conducts studies in virtually all therapeutic areas, including oncology, cardiology, dermatology, infectious diseases, neurosciences, ophthalmology, women's health, pediatrics, and Phase IV development.

Robert Reekie will chair the symposia. Other PharmaNet experts will discuss innovative approaches to concept testing and market authorization including the following topics:

To attend the conference, please contact Klaus Haller at +49 8989557755 or by email khaller@pharmanet.com.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

-- New Scientific and Regulatory Approaches for Flexible Design of Early Stage Trials and Their Preclinical Support, Bengt R. Danielsson, MD, PhD, Vice President, PharmaNet Consulting -- Overview on Global Approaches for Scientific Advice and Regulatory Submissions, Franz Buchholzer, PhD, Vice President, Worldwide Regulatory Operations -- Strategies for Effective Drug Development, Gregory M Hockel, PhD, Executive Vice President, Worldwide Regulatory Operations -- Designing Safe and Efficient Phase I Studies, Mario Tanquay, PhD, BPharmSc, Vice President, Scientific & Regulatory Affairs -- Arriving to the Clinical Side: Trial Design Considerations, Jeff Freitag, MD, Senior Vice President, PharmaNet Consulting

SOURCE PharmaNet Development Group, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Frost & Sullivan: Focus on Product Quality as High...
S
American Lung Association Report Card: Federal Gov...